Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts

International Journal of COPD

Volumn 7, Issue , 2012, Pages 173-182

  Valvi, Deepa ^a   Mannino, David M ^a,b   Müllerova, Hana ^c   Tal Singer, Ruth ^d  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Copd; Epidemiology; Fibrinogen; Hospitalization; Mortality

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; UNITED STATES;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FIBRINOGEN; HOSPITALIZATION; HUMANS; INFLAMMATION MEDIATORS; LINEAR MODELS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84860265548     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S29892     Document Type: Article

References (23)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765-773.
2. Minino AM, Xu J, Kochanek KD. Death in the United States, 2008. Natl Vital Stat Rep. 2010;59(1):1-72.
3. Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet. 1966;1(7442):830-835.
4. Fletcher C, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. Oxford, UK: Oxford University Press; 1976
5. Anthonisen NR. The British hypothesis revisited. Eur Respir J. 2004;23(5):657-658.
6. Vestbo J, Prescott E. Update on the "Dutch hypothesis" for chronic respiratory disease. Thorax. 1998;53 Suppl 2:S15-S19
7. Larsson K. Inflammatory markers in COPD. Clin Respir J. 2008;2 Suppl 1: S84-S87
8. Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS One. 2010;5(7):e11431
9. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(6):1008-1011.
10. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlosser NJ, Wouters EF. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008;133(2):350-357.
11. Jousilahti P, Salomaa V, Hakala K, Rasi V, Vahtera E, Palosuo T. The association of sensitive systemic inflammation markers with bronchial asthma. Ann Allergy Asthma Immunol. 2002;89(4):381-385.
12. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med. 2009;103(8):1231-1238.
13. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129(4):687-702.
14. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263-276.
15. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study-I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost. 1989;61(1):15-19.
16. Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL. Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study. Ann Epidemiol. 1992;2(5):723-733.
17. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41(2):264-270.
18. American Thoracic Society. ATS statement-Snowbird workshop on standardization of spirometry. Am Rev Respir Dis. 1979;119(5): 831-838.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159(1):179-187.
20. Jiang R, Burke GL, Enright PL, et al. Inflammatory markers and longitudinal lung function decline in the elderly. Am J Epidemiol. 2008;168(6):602-610.
21. Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010;11:63
22. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114(9):758-762.
23. Engstrom G, Segelstorm N, Ekberg-Aronsson M, Nilsson PM, Lindgarde F, Lofdahl CG. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax. 2009;64(3):211-215.